12 results for author:"Baudhuin L.M." in Literature citations
Results Customize
› Repeat search in UniProtKB (2)
| Prevalence and spectrum of large deletions or duplications in the major long QT syndrome-susceptibility genes and implications for long QT syndrome genetic testing. Tester D.J., Benton A.J., Train L., Deal B., Baudhuin L.M., Ackerman M.J. Am. J. Cardiol. 106:1124-1128(2010) · Mapped (37) |
| Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure. Baudhuin L.M., Miller W.L., Train L., Bryant S., Hartman K.A., Phelps M., Larock M., Jaffe A.S. Am. J. Cardiol. 106:402-408(2010) · Mapped (37) |
| The value of MUTYH testing in patients with early onset microsatellite stable colorectal cancer referred for hereditary nonpolyposis colon cancer syndrome testing. Riegert-Johnson D.L., Johnson R.A., Rabe K.G., Wang L., Thomas B., Baudhuin L.M., Thibodeau S.N., Boardman L.A. Genet. Test. 11:361-365(2007) · Mapped (9) |
| Comparison of three methods for genotyping the UGT1A1 (TA)n repeat polymorphism. Baudhuin L.M., Highsmith W.E., Skierka J., Holtegaard L., Moore B.E., O'Kane D.J. Clin. Biochem. 40:710-717(2007) · Mapped (15) |
| No title Xu Y., Zhu K., Hong G., Wu W., Baudhuin L.M., Xiao Y.-J., Damron D.S. Nat. Cell Biol. 8:299-299(2006) · UniProtKB (1) |
| MYH Y165C and G382D mutations in hepatocellular carcinoma and cholangiocarcinoma patients. Baudhuin L.M., Roberts L.R., Enders F.T., Swanson R.L., Mettler T.A., Aderca I., Stadheim L.M., Highsmith W.E. J. Cancer Res. Clin. Oncol. 132:159-162(2006) · Mapped (11) |
| Characterization of hMLH1 and hMSH2 gene dosage alterations in Lynch syndrome patients. Baudhuin L.M., Ferber M.J., Winters J.L., Steenblock K.J., Swanson R.L., French A.J., Butz M.L., Thibodeau S.N. Gastroenterology 129:846-854(2005) · Mapped (42) |
| Analysis of hMLH1 and hMSH2 gene dosage alterations in hereditary nonpolyposis colorectal cancer patients by novel methods. Baudhuin L.M., Mai M., French A.J., Kruckeberg K.E., Swanson R.L., Winters J.L., Courteau L.K., Thibodeau S.N. J Mol Diagn 7:226-235(2005) · Mapped (42) |
| MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps. Wang L., Baudhuin L.M., Boardman L.A., Steenblock K.J., Petersen G.M., Halling K.C., French A.J., Johnson R.A., Burgart L.J., Rabe K. et al. Gastroenterology 127:9-16(2004) · Mapped (9) |
| S1P3-mediated Akt activation and cross-talk with platelet-derived growth factor receptor (PDGFR). Baudhuin L.M., Jiang Y., Zaslavsky A., Ishii I., Chun J., Xu Y. FASEB J. 18:341-343(2004) · Mapped (18) |
| Sphingosylphosphorylcholine and lysophosphatidylcholine are ligands for the G protein-coupled receptor GPR4. Zhu K., Baudhuin L.M., Hong G., Williams F.S., Cristina K.L., Kabarowski J.H., Witte O.N., Xu Y. J. Biol. Chem. 276:41325-41335(2001) · UniProtKB (1) |
| Sphingosylphosphorylcholine is a ligand for ovarian cancer G-protein-coupled receptor 1. Xu Y., Zhu K., Hong G., Wu W., Baudhuin L.M., Xiao Y.-J., Damron D.S. Nat. Cell Biol. 2:261-267(2000) · UniProtKB (1) |